Tiplaxtinin (PAI-039) is primarily used in biomedical research as a selective inhibitor of Plasminogen Activator Inhibitor-1 (PAI-1). It is employed to study the role of PAI-1 in various pathological processes such as fibrosis, thrombosis, and cancer progression. By inhibiting PAI-1, Tiplaxtinin enhances fibrinolysis and reduces extracellular matrix accumulation, making it a valuable tool in investigating antifibrotic and antithrombotic therapies. It has shown potential in preclinical models for improving tissue remodeling and reducing organ fibrosis, particularly in the liver and lungs. Additionally, due to PAI-1's involvement in tumor cell invasion and metastasis, Tiplaxtinin is used to explore its effects on cancer cell migration and angiogenesis. Its application remains largely experimental, focused on understanding disease mechanisms and supporting drug development.